Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial

por Shitara, Kohei, Hara, Hiroki, Yoshikawa, Takaki, Fujitani, Kazumasa, Nishina, Tomohiro, Hosokawa, Ayumu, Asakawa, Takashi, Kawakami, Satoe, Muro, Kei
Publicado 2019

Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm

por Narita, Yusuke, Yoshimoto, Takuya, Namai, Tomoyuki, Asakawa, Takashi, Kawakami, Satoe, Gower-Page, Craig, Reyes-Rivera, Irmarie, Patel, Arisha, Nakamura, Yoshiaki
Publicado 2022